Press Releases

Date Title and Summary Additional Formats
Toggle Summary Biocept Reports Second Quarter 2018 Financial Results
Company to host conference call at 4:30 p.m. Eastern time today SAN DIEGO , Aug. 14, 2018 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer
View HTML
Toggle Summary Biocept to Release Second Quarter 2018 Financial Results and Host Investor Conference Call on August 14, 2018
SAN DIEGO , Aug. 9, 2018 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable information to physicians to improve cancer treatment, announces that it will release financial
View HTML
Toggle Summary Biocept Announces $11.6 Million in Expected Gross Proceeds from Recently Expired Rights Offering
SAN DIEGO , Aug. 9, 2018 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announced today that the Company's previously announced
View HTML
Toggle Summary Biocept Announces Agreement with Managed Care Plan to Study the Benefits of Implementing Liquid Biopsy to Improve Patient Outcomes and Lower Healthcare Costs
Biocept's Target Selector™ to be used in profiling and monitoring patients diagnosed with non-small cell lung cancer throughout an integrated healthcare delivery system SAN DIEGO , Aug. 6, 2018 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests
View HTML
Toggle Summary Biocept Awarded Patent in Canada for its Target Selector CTC Platform
Further expands global patent estate for capturing and detecting biological targets of interest including rare cells such as circulating tumor cells (CTCs) SAN DIEGO , Aug. 2, 2018 /PRNewswire/ --  Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to
View HTML
Toggle Summary European Patent Granted for Biocept's Target Selector Oncogene Mutation Enrichment and Detection Platform
Expands intellectual property to 27 issued patents globally for highly sensitive methods of detecting cancer biomarkers in circulating tumor DNA (ctDNA) and on circulating tumor cells (CTCs) SAN DIEGO , July 31, 2018 /PRNewswire/ --  Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of
View HTML
Toggle Summary Biocept and UC San Diego Moores Cancer Center Announce Collaboration to Study Feasibility of Liquid Biopsy to Predict Disease Recurrence in Solid Tumors and Response to Therapy
Clinical studies with Biocept's Target Selector™ to evaluate the use of circulating tumor cells in disease assessment, surveillance and monitoring SAN DIEGO , July 23, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide
View HTML
Toggle Summary Biocept Reminds Investors of Today's Deadline to be a Shareholder of Record
To be a shareholder of record, investors are advised to own Biocept stock by 4:00 PM ET, Thursday, July 19, 2018 to account for T+2 settlement timing Record date established as Monday, July 23, 2018 SAN DIEGO , July 19, 2018 /PRNewswire/ -- Biocept, Inc.
View HTML
Toggle Summary Biocept Enters into Agreement with Alliance Global FZ to Market and Distribute Liquid Biopsy Testing in the Middle East, Southeast Asia, and Africa Region
Expands international distribution of Target Selector™ platform to 17 countries SAN DIEGO , July 13, 2018 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes
View HTML
Toggle Summary Biocept Informs Stockholders of Key Dates and Terms Related to Announced Rights Offering
SAN DIEGO , July 11, 2018 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC) (" Biocept "), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, today provided an
View HTML